Full Schedule

Home
Full Schedule

All Days
Wed, May 3
Thu, May 4
Fri, May 5
On-Demand

Full Schedule

Type here to filter the list

Friday, May 5, 2023
9:00 AM – 9:15 AM ET
Welcome and Introduction

9:00 AM – 9:15 AM ET

Welcome and Introduction
Time Zone: ET

9:15 AM – 9:50 AM ET
Session 16: HER2-Positive Metastatic Breast Cancer: Where Are We Headed?

9:15 AM – 9:50 AM ET

Session 16: HER2-Positive Metastatic Breast Cancer: Where Are We Headed?
Time Zone: ET

Presenter: Sara Hurvitz, MD – University of California, Los Angeles

Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###
Presenter: Sara Hurvitz, MD – University of California, Los Angeles
###

9:50 AM – 10:00 AM ET
Live Q&A

9:50 AM – 10:00 AM ET

Live Q&A
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Speaker: Sara Hurvitz, MD – University of California, Los Angeles

10:00 AM – 10:15 AM ET
Break

10:00 AM – 10:15 AM ET

Break
Time Zone: ET

10:15 AM – 11:15 AM ET
Case-Based Discussion on Management of Select Adverse Events

10:15 AM – 11:15 AM ET

Non-CME Innovation Theater
Time Zone: ET

11:15 AM – 11:30 AM ET
Break

11:15 AM – 11:30 AM ET

Break
Time Zone: ET

11:30 AM – 12:05 PM ET
Session 17: Immunotherapy for Breast Cancer

11:30 AM – 12:05 PM ET

Session 17: Immunotherapy for Breast Cancer
Time Zone: ET

Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC

Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###
Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC
###

12:05 PM – 12:15 PM ET
Live Q&A

12:05 PM – 12:15 PM ET

Live Q&A
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Speaker: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC

12:15 PM – 12:30 PM ET
Break

12:15 PM – 12:30 PM ET

Break
Time Zone: ET

12:30 PM – 1:15 PM ET
Session 18: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc

12:30 PM – 1:15 PM ET

Session 18: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc

Presenter: Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology

Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Presenter###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###
Presenter: Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
###

1:15 PM – 1:35 PM ET
Break

1:15 PM – 1:35 PM ET

Break
Time Zone: ET

1:35 PM – 1:50 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - YES

1:35 PM – 1:50 PM ET

Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - YES
Time Zone: ET

Presenter: David Cescon, MD, PhD – Princess Margaret Cancer Centre

David Cescon, MD, PhD – Princess Margaret Cancer Centre ### 1765982###Presenter###Medical Oncologist and Clinician Scientist###Princess Margaret Cancer Centre###
Presenter: David Cescon, MD, PhD – Princess Margaret Cancer Centre
###

1:50 PM – 2:05 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - NO

1:50 PM – 2:05 PM ET

Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - NO
Time Zone: ET

Presenter: Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School

Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School ### 1744695###Presenter###Director, Termeer Center for Targeted Therapies###Mass General Cancer Center, Harvard Medical School###
Presenter: Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School
###

2:05 PM – 2:25 PM ET
Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - DISCUSSION

2:05 PM – 2:25 PM ET

Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - DISCUSSION
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Panelist: David Cescon, MD, PhD – Princess Margaret Cancer Centre

Panelist: Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School

Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ David Cescon, MD, PhD – Princess Margaret Cancer Centre ### 1765982###Panelist###Medical Oncologist and Clinician Scientist###Princess Margaret Cancer Centre###
Panelist: David Cescon, MD, PhD – Princess Margaret Cancer Centre
### @@@ Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School ### 1744695###Panelist###Director, Termeer Center for Targeted Therapies###Mass General Cancer Center, Harvard Medical School###
Panelist: Dejan Juric, MD – Mass General Cancer Center, Harvard Medical School
###

2:20 PM – 2:45 PM ET
Break

2:25 PM – 2:45 PM ET

Break
Time Zone: ET

2:45 PM – 3:20 PM ET
Session 20: Beyond Immunotherapy: Novel Agents in TNBC

2:45 PM – 3:20 PM ET

Session 20: Beyond Immunotherapy: Novel Agents in TNBC
Time Zone: ET

Presenter: Rita Nanda, MD – The University of Chicago

Rita Nanda, MD (she/her/hers) – The University of Chicago ### 1949812###Presenter###Director of Breast Oncology, Associate Professor of Medicine###The University of Chicago###
Presenter: Rita Nanda, MD (she/her/hers) – The University of Chicago
### she/her/hers

3:20 PM – 3:30 PM ET
Live Q&A

3:20 PM – 3:30 PM ET

Live Q&A
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Speaker: Rita Nanda, MD – The University of Chicago

3:30 PM – 3:45 PM ET
Break

3:30 PM – 3:45 PM ET

Break
Time Zone: ET

3:45 PM – 4:20 PM ET
Session 21: Biosimilars in Breast Cancer Therapy

3:45 PM – 4:20 PM ET

Session 21: Biosimilars in Breast Cancer Therapy
Time Zone: ET

Presenter: William Gradishar, MD, FASCO, FACP

William Gradishar, MD, FASCO, FACP ### 1929925###Presenter#########
Presenter: William Gradishar, MD, FASCO, FACP
###

4:20 PM – 4:30 PM ET
Live Q&A

4:20 PM – 4:30 PM ET

Live Q&A
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Speaker: William Gradishar, MD, FASCO, FACP

4:30 PM – 4:45 PM ET
Break

4:30 PM – 4:45 PM ET

Break
Time Zone: ET

4:45 PM – 5:20 PM ET
Session 22: HER2-Low Breast Cancer: Limits of Testing and Where to Go from Here

4:45 PM – 5:20 PM ET

Session 22: HER2-Low Breast Cancer: Limits of Testing and Where to Go from Here
Time Zone: ET

Presenter: Paolo Tarantino, MD – Dana-Farber Cancer Institute, Harvard Medical School

Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###
Presenter: Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his

5:20 PM – 5:30 PM ET
Live Q&A

5:20 PM – 5:30 PM ET

Live Q&A
Time Zone: ET

Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)

Speaker: Paolo Tarantino, MD – Dana-Farber Cancer Institute, Harvard Medical School

Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Speaker###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###
Speaker: Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his